Christophe

Affluent Medical : 2023 financial results and update on clinical activities under development.

Retrieved on: 
Friday, May 3, 2024
Medtech, FDA, Risk, De novo, Death, Mitral regurgitation, Doctor of Philosophy, Wound healing, Mitral valve annuloplasty, Boston Scientific, Ticker, Wealth, Urinary incontinence, Woman, Christophe, Food, Neurostimulation, Myocardial infarction, Aix-en-Provence, DSM-IV codes, LCEA, Mitral valve, TAVI, Minerva, Certification, Heart, Quality assurance, System, Anatomy, Exercise, NYHA, Dry, Marketing, Clinical trial, American College, Development director, MD, Endocarditis, Medtronic, Patient, Tricuspid valve, Acquisition, Medical device

Affluent Medical : 2023 financial results and update on clinical activities under development.

Key Points: 
  • Affluent Medical : 2023 financial results and update on clinical activities under development.
  • Affluent Medical estimates that KaliosTM would avoid repeat surgery for 30-40% of patients within five years of their operation.
  • In September 2023, the Company presented interim data on 20 patients treated in five clinical centers in Europe after one year of implantation.
  • In July 2023, Affluent Medical announced the appointments of Christophe de Vregille as Chief Financial Officer and Benjamin Renault as Development Director.

Decomposing systemic risk: the roles of contagion and common exposures

Retrieved on: 
Tuesday, April 23, 2024
Tao, CIBC, Tax, RWA, Risk, European Systemic Risk Board, Research Papers in Economics, Contagion, RT, The Big Six, NBC, International, Shock, Observation, Bank of Canada, HTC, European Economic Association, The Washington Post, Great, JPMorgan Chase, Paper, GM, Environment, Political economy, Journal of Financial Economics, COVID-19, Perception, BNS, Website, Silicon, IAT, Cifuentes, Probability, Balance sheet, RAN, Medical classification, Algorithm, Information technology, Quarterly Journal of Economics, LN, Nature, European Journal, Royal Bank of Canada, Technical report, Journal of Political Economy, Equitable Bank, Bankruptcy, RAI, PDF, Private, ECB, Policy, CHS, Supercapacitor, Social science, Journal of Financial Stability, Intelligence (journal), Elsevier, Home, Cambridge University Press, Journal, Springer Science+Business Media, Research, Classification, Regulation, News, EQB, Credit, Literature, AIK, European Central Bank, COVID, SVAR, Section 5, Management science, DRA, M4, VL, National bank, Government, ISSN, BMO, Panel, International Financial Reporting Standards, BIS, FIS, Basel III, Commerce, Scotiabank, C32, Econometric Society, Interbank, Fraud, Section 4, Bank, Schedule, VAR, Section 3, The Journal of Finance, RBC, Volcanic explosivity index, Fire, Wassily Leontief, Financial economics, Metric, Section 2, L14, Central bank, Superintendent, Bank of Montreal, Kronecker, BOC, Lithium, BCBS, Sale, Macroeconomic Dynamics, Christophe, CWB, LBC, NHA, Imperial Bank, Private equity, Quarterly Journal, National Bank of Canada, C51, Canadian Western Bank, Currency crisis, JEL classification codes, Victor Drai, L.1, MFC, Silicon Valley Bank, EB, Laurentian Bank of Canada, Federal, RA1, Series, W0, FEVD, Journal of Econometrics, Aggregate, University, FRB, MB, Financial institution, Element, Health, Book, Angels & Airwaves, Common, OSFI, GFC, Reproduction, K L, Systematic, Housing, G21, Home Capital Group, Communications satellite

Abstract

Key Points: 
    • Abstract
      We evaluate the effects of contagion and common exposure on banks? capital through
      a regression design inspired by the structural VAR literature and derived from the balance
      sheet identity.
    • Contagion can occur through direct exposures, fire sales, and market-based
      sentiment, while common exposures result from portfolio overlaps.
    • First, we document that contagion varies in time, with the highest levels
      around the Great Financial Crisis and lowest levels during the pandemic.
    • Our new framework complements
      traditional stress-tests focused on single institutions by providing a holistic view of systemic risk.
    • While existing literature presents various contagion narratives, empirical findings on
      distress propagation - a precursor to defaults - remain scarce.
    • We decompose systemic risk into three elements: contagion, common exposures, and idiosyncratic risk, all derived from banks? balance sheet identities.
    • The contagion factor encompasses both sentiment- and contractual-based elements, common exposures consider systemic
      aspects, while idiosyncratic risk encapsulates unique bank-specific risk sources.
    • Our empirical analysis of the Canadian banking system reveals the dynamic nature of contagion, with elevated levels observed during the Global Financial Crisis.
    • In conclusion, our model offers a comprehensive lens for policy intervention analysis and
      scenario evaluations on contagion and systemic risk in banking.
    • This
      notion of systemic risk implies two key components: first, systematic risks (e.g., risks related
      to common exposures) and second, contagion (i.e., an initially idiosyncratic problem becoming
      more widespread throughout the financial system) (see Caruana, 2010).
    • In this paper, we decompose systemic risk into three components: contagion, common exposures, and idiosyncratic risk.
    • First, we include contagion in three forms: sentiment-based contagion, contractual-based
      contagion, and price-mediated contagion.
    • In this context,
      portfolio overlaps create common exposures, implying that bigger overlaps make systematic
      shocks more systemic.
    • With the COVID-19 pandemic starting
      in 2020, contagion drops to all time lows, potentially related to strong fiscal and monetary
      supports.
    • That is, our
      structural model provides a framework for analyzing the impact of policy interventions and
      scenarios on different levels of contagion and systemic risk in the banking system.
    • This provides a complementary approach to
      seminal papers that took a structural approach to contagion, such as DebtRank Battiston et al.
    • More generally, the literature on networks and systemic risk started with Allen and Gale
      (2001) and Eisenberg and Noe (2001).
    • The matrix is structured as follows:
      1

      In our model, we do not distinguish between interbank liabilities and other types of liabilities.

    • In other words, we can and aim to estimate different degrees
      of contagion per asset class, i.e., potentially distinct parameters ?Ga .
    • For that, we build three major
      metrics to check: average contagion, average common exposure, and average idiosyncratic risk.
    • N i j

      et ,
      Further, we define the (N ?K) common exposure matrix as Commt = [A

      (20)

      et ]diag (?C
      ?L

      such that average common exposure reads,
      average common exposure =

      1 XX
      Commik,t .

    • N i j

      (22)

      20

      ? c ),

      The three metrics?average contagion, average common exposure, and average idiosyncratic risk?provide a comprehensive framework for understanding banking dynamics.

    • Figure 4 depicts the average level of risks per systemic risk channel: contagion risk, common exposure, and idiosyncratic risk.
    • Figure 4: Average levels of contagion (Equation (20)), common exposure (Equation (21)), and idiosyncratic risk
      (Equation (22)).
    • The market-based contagion is the contagion due to
      investors? sentiment, and the network is an estimate FEVD on volatility data.
    • For most of
      the sample, we find that contagion had a bigger impact on the variance than common exposures.

NRC Health Expands Leadership Team to Accelerate Innovation, Meet Growing Demand for Insights and Solutions

Retrieved on: 
Thursday, February 1, 2024
Professional Services, Health, Data Analytics, Hospitals, Practice Management, Health Technology, Managed Care, Christophe, Growth, IA Financial Group, ARR, Family, Marketing, History, Press Ganey Associates, Walking, Connect, Cooking, B2B, Patient, Computer science, Skiing, Melissa, Friends, MBA, NRC, Gallup, Inc., Ball State University, AEGON, University, Human, Advertising, National Research Corporation, Ball, Business, Organization, Hospital, Management

NRC Health, the leading provider of human-centered healthcare solutions and data-driven insights, is elevating its leadership team with the appointment of four executive-officer positions.

Key Points: 
  • NRC Health, the leading provider of human-centered healthcare solutions and data-driven insights, is elevating its leadership team with the appointment of four executive-officer positions.
  • The strategic move will allow NRC Health to accelerate innovation while continuing to provide exceptional customer experiences to its partners.
  • Christophe Louvion brings decades of executive leadership skills to his role as Chief Product and Technology Officer at NRC Health.
  • During his career, he has held consulting and leadership positions at Practicing Excellence, NRC Health, Connect, AEGON, and the Gallup Organization.

ASML Supervisory Board intends to appoint Christophe Fouquet as President and Chief Executive Officer

Retrieved on: 
Thursday, November 30, 2023
Christophe Fouquet, Partnership, DUV, Acquisition, ASML Holding, Christophe, Heart, Human, Collaboration, Supervision, Engineering, Annual, Supervisory board, EUV, ASML, Management

ASML’s Co-Presidents Peter Wennink and Martin van den Brink to retire on April 24, 2024

Key Points: 
  • ASML’s Co-Presidents Peter Wennink and Martin van den Brink to retire on April 24, 2024
    VELDHOVEN, the Netherlands, November 30, 2023 – The Supervisory Board of ASML Holding NV (ASML) announces that it intends to appoint Christophe Fouquet, currently ASML’s Chief Business Officer and member of the Board of Management, as the company’s next President and Chief Executive Officer.
  • On the same date, ASML’s Co-Presidents Peter Wennink and Martin van den Brink will retire from ASML upon completion of their current appointment terms.
  • Nils Andersen, Chairman of the Supervisory Board, said: “The Supervisory Board, together with the management team, has gone through a comprehensive succession planning process.
  • Christophe has been with ASML for 15 years, with a major focus on ASML technology, products and customers.

X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Thursday, November 9, 2023
Priority review, FDA, Ageing, PDUFA, Addition, Rare, Physician, Christophe, SG, MD, Conference, Organization, Doctor of Philosophy, PRV, Primary immunodeficiency, R, Society, Neutropenia, ASH, Wart, WHIM, Disease, ID, WHIM syndrome, Immune system, Research and development, Line, File, Security (finance), New Drug Application, NDA, Safety, Conference call, Patient, Diagnosis, State Administrative Expenses, Pharmaceutical industry, Rare-earth element, Hypogammaglobulinemia, Infection, Myelokathexis

BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the third quarter ended September 30, 2023 and highlighted key recent and upcoming expected milestones.

Key Points: 
  • ET
    BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the third quarter ended September 30, 2023 and highlighted key recent and upcoming expected milestones.
  • The FDA has notified X4 that it does not currently plan to hold an advisory committee meeting to review the filing.
  • Cash, Cash Equivalents, Restricted Cash, and Short-Term Marketable Securities: X4 had $142.7 million in cash, cash equivalents, restricted cash, and marketable securities as of September 30, 2023.
  • The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com .

Last chance to win one of four replica championship bicycles

Retrieved on: 
Tuesday, September 19, 2023
Christophe, British Championship, Freedom, Elite, Education, Health, World Bicycle Relief, Edinburgh Global Partnerships, World cup, UCI Cycling World Championships, Woman, Carbon, Courtney, Athlete, UCI, Tour de France Femmes, SRAM, Engineering, TREK, Kate Courtney, Safety, Empowerment, Bicycle

CHICAGO, Sept. 19, 2023 /PRNewswire/ --Women's cycling is currently enjoying a remarkable surge in popularity and success, thanks in no small part to the achievements of four exceptional women. On a bicycle women can achieve amazing things, as demonstrated by the incredible careers of professional cyclists Annemiek van Vleuten, Marianne Vos, Kate Courtney, and Evie Richards.

Key Points: 
  • Each of these remarkable athletes, in collaboration with their brand sponsors, provided a replica of the bicycle they used during the Championships.
  • World Bicycle Relief is a global nonprofit organization dedicated to providing access to education, healthcare, and economic opportunities through the power of bicycles.
  • By raffling these exclusive replica championship bicycles, World Bicycle Relief aims to raise critical funds to continue its mission.
  • To enter the raffle for a chance to win one of these four replica championship bicycles, simply support World Bicycle Relief through viprize.org/wbr .

Slone Partners Places Christophe Arbet-Engels as Chief Medical Officer at X4 Pharmaceuticals

Retrieved on: 
Thursday, August 31, 2023
Christophe, Roche, Therapy, Biogen, Biotechnology, Slone, Research, CMO, Doctor of Philosophy, Merck & Co., X4, Boehringer Ingelheim, MD, Patient, Immune system, Management, Fine chemical, Ligand Pharmaceuticals

SOUTH RIDING, Va., Aug. 31, 2023 /PRNewswire-PRWeb/ -- Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and healthcare companies, today announced the successful placement of Christophe Arbet-Engels, MD, PhD, as Chief Medical Officer (CMO) at X4 Pharmaceuticals, Inc., a biopharmaceutical company developing novel small molecule therapeutics to benefit patients with diseases of the immune system.

Key Points: 
  • SOUTH RIDING, Va., Aug. 31, 2023 /PRNewswire-PRWeb/ -- Slone Partners , a nationwide executive search firm for life sciences, biotechnology, and healthcare companies, today announced the successful placement of Christophe Arbet-Engels , MD, PhD, as Chief Medical Officer (CMO) at X4 Pharmaceuticals, Inc. , a biopharmaceutical company developing novel small molecule therapeutics to benefit patients with diseases of the immune system.
  • Dr. Arbet-Engels is a highly respected and experienced global pharmaceutical executive with keen business acumen honed over more than 20 years serving in complex organizational settings," said Leslie Loveless, Slone Partners CEO.
  • "Dr. Arbet-Engels is a highly respected and experienced global pharmaceutical executive with keen business acumen honed over more than 20 years serving in complex organizational settings," said Leslie Loveless , Slone Partners CEO.
  • "It was truly a pleasure collaborating with Slone Partners on the placement of Christophe as our new Chief Medical Officer," said Paula Ragan , Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals, "We very much value our relationship with the Slone team and consider them a valuable ongoing resource to X4 given their deep understanding of and high quality connections within the life science industry."

X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program

Retrieved on: 
Thursday, August 10, 2023
Addition, Christophe, Maintenance, ANC, Priority review, Therapy, SG, European Hematology Association, Line, Conference call, Federation of Clinical Immunology Societies, Neutropenia, PIPE, Disclosure, Clinical trial, CIS, Research, Cash, Doctor of Philosophy, ID, Research and development, State Administrative Expenses, Russell, MD, Physician, Patient, WHIM syndrome, Patent, Immune system, Annual Meetings of the International Monetary Fund and the World Bank Group, EHA, Growth, Wart, G-CSF, R, Rare, Restricted, Conference, Safety, Pharmaceutical industry, Cryptocurrency, Bank, Infection, Hypogammaglobulinemia

Additional data from this ongoing Phase 2 trial are expected to be shared in the fourth quarter of 2023.

Key Points: 
  • Additional data from this ongoing Phase 2 trial are expected to be shared in the fourth quarter of 2023.
  • X4 is planning to initiate a Phase 3 clinical trial evaluating mavorixafor in certain chronic neutropenic disorders in the first half of 2024.
  • X4 will host a conference call and webcast today at 8:30 am ET to discuss these financial results and business highlights.
  • The live webcast and slide presentation can be accessed on the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com .

EQS-News: Affluent Medical strengthens management team to advance its development

Retrieved on: 
Monday, July 17, 2023
Edwards, Christophe, IPO, CET, Fresenius (company), Pathology, Merck Group, Vregille, Doctor of Philosophy, CDO, Euronext Paris, Medtronic, Patient, CFO, Knowledge, Growth, Wealth, Johnson & Johnson, Regulatory affairs, VTC, Aix-en-Provence, Medtech, Covidien, BD, Urinary incontinence, Pharmaceutical industry, Management

Sébastien Ladet, CEO of Affluent Medical, commented: "I am delighted to welcome Christophe de Vregille and Benjamin Renault to the Affluent Medical management team at a time when we are approaching several decisive stages in the deployment of our development strategy.

Key Points: 
  • Sébastien Ladet, CEO of Affluent Medical, commented: "I am delighted to welcome Christophe de Vregille and Benjamin Renault to the Affluent Medical management team at a time when we are approaching several decisive stages in the deployment of our development strategy.
  • Benjamin brings a wealth of experience and knowledge in medical device development, which will be instrumental in preparing for commercialization and our expansion on international markets."
  • Benjamin Renault has over 15 years' experience in the development and international deployment of medical devices.
  • Overview of Affluent Medical’s management and leadership team:
    Christophe Giot, M.D., Chief Medical Officer and Vice President Clinical Affairs (Edwards, Terumo, Sanofi)
    Céline Buard, Marketing Director (Johnson & Johnson, BD, Eyetech Care)
    Eric Jague, Director of Regulatory Affairs (Medtronic, Fresenius Kabi)

Affluent Medical strengthens management team to advance its development.

Retrieved on: 
Monday, July 17, 2023
Edwards, Christophe, IPO, CET, Fresenius (company), Pathology, Merck Group, Vregille, Doctor of Philosophy, CDO, Euronext Paris, Medtronic, Patient, Regulatory News Service, CFO, Knowledge, Growth, Wealth, Johnson & Johnson, Regulatory affairs, VTC, Aix-en-Provence, Medtech, Covidien, BD, Urinary incontinence, Risk management, Pharmaceutical industry, Management

Affluent Medical strengthens management team to advance its development.

Key Points: 
  • Affluent Medical strengthens management team to advance its development.
  • Sébastien Ladet, CEO of Affluent Medical comments: "I am delighted to welcome Christophe de Vregille and Benjamin Renault to the Affluent Medical management team at a time when we are approaching several decisive stages in the deployment of our development strategy.
  • Benjamin Renault has over 15 years' experience in the development and international deployment of medical devices.
  • Overview of Affluent Medical’s management and leadership team:
    Christophe Giot, M.D., Chief Medical Officer and Vice President Clinical Affairs (Edwards, Terumo, Sanofi)
    Céline Buard, Marketing Director (Johnson & Johnson, BD, Eyetech Care)
    Eric Jague, Director of Regulatory Affairs (Medtronic, Fresenius Kabi)